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Abstract
The gut microbiota plays a key role in the development of chronic inflammatory liver disease. The 
gut-liver axis involves inflammatory cells, cytokines, and other molecules that cause liver deteriora-
tion. Dysbiosis is important in understanding several liver diseases, especially in relation to the 
development of autoimmune liver disease. The aim of this review is to provide a current overview 
of alterations in the gut and oral microbiota associated with autoimmune liver diseases.
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Introduction
Primary biliary cholangitis (PBC) and autoim-
mune hepatitis (AIH) are classically viewed as distinct 
autoimmune liver diseases. Autoimmune liver dis-
eases are thought to be triggered by environmental 
factors in genetically susceptible individuals. Ge-
nome-wide association and murine model studies 
have expanded our knowledge of autoimmune liver 
diseases, however, the pathogenesis of disease re-
mains obscure. Recently culture-independent 
techniques have revolutionized knowledge of the gut 
and oral microbiota. This review provides an over-
view of gut and oral microbiota in autoimmune liver 
diseases.
Gut-Liver axis
The gut and liver are closely related. The liv-
er is significantly affected by the gut and its con-
tents, as 70% of the blood supplied to the liver is 
collected from intestinal circulation through the por-
tal venous system. Both the gut and liver play a 
pivotal role in the absorption and metabolism of vari-
ous nutrients and drugs. Abnormal bile acid ho-
meostasis may lead to diarrhea and bacterial over-
growth1). Bacterial overgrowth, increased intestinal 
permeability, failure to inactivate endotoxins, and ac-
tivated innate immunity all contribute to the patho-
logical state of bacterial translocation.
Gut and oral microbiota
The gut microbiota collectively refers to the 
100 trillion bacteria, with an estimated mass of 1-2 
kg, that inhabit the human gastrointestinal tract. 
This very diverse ecosystem comprises over 2,000 
distinct species and has a collective genome contain-
ing 150-fold more genes than the human ge-
nome2). The metabolic activity of the gut microbio-
ta provides benefits to human health by supplying 
essential nutrients and maximizing the efficiency of 
energy harvest from ingested food. However, the 
microbiota also contains numerous potential oppor-
tunistic pathogens. Moreover, gut microbial prod-
ucts activate Toll-like receptors (TLRs) and induce 
inflammation that defines disease. Maintaining the 
homeostasis of the gut microbiota has thus necessi-
tated the development of a specialized mucosal im-
mune system3). Characterization of the microbiota 
has been performed by culture and biochemical typ-
ing, which have been gold standards for the identifi-
cation of bacterial species. Recently, however, ad-
vances in culture-independent techniques have 
revolutionized our knowledge about the gut microbi-
ota. These techniques, based on sequence diver-
Corresponding author : Kazumichi Abe, MD E-mail : k-abe@fmu.ac.jp
https://www.jstage.jst.go.jp/browse/fms http://www.fmu.ac.jp/home/lib/F-igaku/
71
72 K. Abe et al.
gences in the small subunit ribosomal ribonucleic 
acid (16S rRNA), allow the demonstration of gut mi-
crobial diversity, providing qualitative and quantita-
tive information on bacterial species as well as alter-
ations in the gut microbiota in healthy and diseased 
states4).
The oral cavity is a large reservoir of bacteria of 
more than 700 species or phylotypes and is pro-
foundly relevant to host health and disease5-7). The 
role of the oral and gut microbiota in the pathogene-
sis of immune-related diseases has been highlighted 
in autoimmune diseases, such as autoimmune en-
cephalomyelitis, rheumatoid arthritis, and inflamma-
tory bowel disease8-14). A previous report revealed 
evidence of pervasive changes in the immune sys-
tem-microbiota interface in the saliva of patients 
with cirrhosis that were similar to those found in 
stool15).
Gut and oral microbiota in AIH
AIH manifests as chronic liver inflammation of 
an unknown cause. It generally affects young to 
middle-aged females and is associated with the 
presence of autoantibodies and hypergammaglobu-
linemia16). However, the pathogenesis of this dis-
ease remains obscure. It is increasingly recog-
nized that the composition of the gut microbiota 
plays a critical role in influencing the predisposition 
to AIH17-21) (Table 1). In addition, an increase in the 
abundance of Veillonella dispar was associated with 
disease severity, and the metagenomic profile sug-
gests that this bacterium may be involved in lipo-
polysaccharide (LPS) biosynthesis and amino acid 
metabolism20). Lin R et al. reported that increased 
intestinal permeability and bacterial translocation 
occurred in AIH, wihich associated with disease se-
verity17). However, direct evaluation of the oral mi-
crobiome has not been performed in AIH. Our data 
indicated a significant increase in the abundance of 
the genus Veillonella in the oral microbiota of pa-
tients with AIH, and the abundance of the genus 
Veillonella was positively correlated with the levels 
of proinflammatory cytokines, such as IL-1β, IL-6, 
IL-8, and IL-12p70 in the saliva of patients with 
AIH21) (Figure 1a). However, it is unknown wheth-
er the inflammatory state in the oral cavity of AIH 
patients is the cause or consequence of imbalances 
in the salivary microbiota and whether the oral cavi-
ty or the gut immune response exerts greater influ-
ence on the observed dysbiosis of the oral microbio-
ta. In our study, changes in the gut microbiota 
composition in AIH were characterized by an in-
crease in abundance of the order Lactobacillales and 
Table 1. Changes in the gut and oral microbiota associated with autoimmune liver diseases
 Gut microbiota
Disease Comparison Genus (or Order) Author/year
AIH (n=24) Healthy vs AIH Lactobacillus↓
Bifidobacterium ↓ Lin/2015
17)
AIH (n=17) Healthy vs AIH Lactobacillales↑Clostridium subcluster XIVa ↓ Abe/2018
21)
AIH (n=99) Healthy vs AIH
Veillonella↑, Lactobacillus↑, Streptococcus↑,
Klebsiella↑, Oscillospira↓, Parabacteroides↓, 
 Coprococcus ↓
Wei/201920)
PBC (n=79) Healthy vs PBC
Enterobacteriaceae↑ Klebsiella↑, 
Haemophilus↑ Veillonella↑,
Clostridium↑ Lactobacillus↑,
Streptococcus↑, Pseudomonas↑,
Bacteroidetes↓, Sutterella↓
 Oscillospira↓, Faecalibacterium↓
Tang/201726)
PBC (n=39) Healthy vs PBC Lactobacillales↑Clostridium subcluster XIVa↓ Abe/2018
21)
 Oral microbiota
Disease Comparison Genus (or Order) Author/year
AIH (n=17) Healthy vs AIH Veillonella↑, Streptococcus↓,Fusobacterium↓ Abe/2018
21)
PBC (n=39) Healthy vs PBC Veillonella↑, Eubacterium↑Fusobacterium↓ Abe/2018
21)
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a decreased abundance of the genus Clostridium 
subcluster XIVa21) (Figure 1b). Interestingly, our 
study suggested that the relative abundance of Lac-
tobacillales in feces was positively correlated with 
the relative abundance of Veillonella in saliva from 
patients with AIH (Figure 2). Lactobacillus species 
had relatively large effect sizes in Behcet’s disease 
microbiota, consistent with the inductive effect of 
Lactobacillus on systemic inflammation. Animal 
studies using germ-free mice reported that some 
bacterial species independently promoted arthritis 
by activating Th17 cells22,23). Dysbiosis of the oral 
microbiota is directly and/or indirectly related to the 
gut microbiota and may be correlated with disease 
onset.
Gut and oral microbiota in PBC
PBC is a progressive autoimmune liver disease 
characterized by portal inflammation, immune-medi-
ated destruction of the intrahepatic bile ducts, and 
the presence of highly specific anti-mitochondrial 
antibodies in serum24,25). Tang R et al. reported that 
the 16S rRNA gene was analyzed longitudinally by 
next-generation sequencing (NGS) in PBC patients 
before treatment with ursodeoxycholic acid (UDCA) 
using stools of 114 healthy subjects matched in age, 
gender and body mass index with 79 patients with 
naive PBC. The number and diversity of observed 
operational taxonomic units (OTUs) were signifi-
cantly reduced in the naive PBC patients. The re-
sults of principal component analysis by calculating 
the UniFrac distance showed that the distribution 
was significantly different between the naive pa-
tients with PBC and the healthy subjects. The ex-
ploration cohort and the verification cohort had simi-
lar results26). Moreover, to investigate the changes 
in specific gut microbiota components in naive PBC 
patients, the relative abundance of bacteria at the 
genus level was compared with that of the healthy 
subjects. At the genus level, there were changes in 
the relative abundances of 12 bacteria in naïve pa-
tients with PBC compared to healthy subjects. 
Eight bacteria (Haemophilus, Veillonella, Clostridium, 
Fig. 1. Analysis of the gut and oral microbiota of the PBC, AIH and HC groups based on the T-RFLP profiles.  
(a) Mean genus abundance of oral microbiota in the PBC, AIH and HC groups. The plotted values are the mean 
abundance values of the 8 abundant genera in each group. (b) Mean genus or order abundance of gut microbiota 
in the PBC, AIH and HC groups. The plotted values are the mean abundance values of the 8 abundant genera 
and 1 abundant order in each group. The results are expressed as the means ± SDs. Differences were com-
pared using the Mann-Whitney U test ; *P<0.05, **P<0.01, ***P<0.0005.
Fig. 2. Correlation between the gut microbiota and 
oral microbiota in AIH patients.
 The relative abundance of Lactobacillales in feces 
was positively correlated with the relative abun-
dance of Veillonella in saliva from patients with 
AIH. The P-value was calculated with the Spear-
man rank correlation test. P<0.05 was consid-
ered significant.
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Lactobacillus, Streptococcus, Pseudomonas, Klebsiella, 
and Enterobacteriaceae) had increased relative abun-
dances, and four (Sutterella, Oscillospira, Faecalibac-
terium, and Bacteroides) had decreased relative 
abundances (Table 1).
Our study indicated that there was a significant-
ly higher frequency of bacteria in the genus Veillon-
ella and the genus Eubacterium and a lower frequen-
cy of bacteria in the genus Fusobacterium in the PBC 
group than in the healthy subjects (Figure 1a). 
Moreover, the changes in the gut microbiota compo-
sition in PBC were characterized by an increase in 
the abundance of the order Lactobacillales and by a 
decrease in the abundance of the genus Clostridium 
subcluster XIVa (Figure 1b). The relative abun-
dance of Streptococcus was negatively correlated 
with the levels of IL-1β, IL-4, IL-6, IL-7, IL-8, IL-
12p70, IL-17, G-CSF, IFN-γ and TNF-α, while the 
relative abundances of Veillonella and Prevotella/Por-
phyromonas were positively correlated with the IgA 
level in the saliva of patients with PBC. Moreover, 
the relative abundances of Neisseria and Eubacteri-
um/Filifactor were positively correlated with the sal-
ivary cytokine levels in patients with PBC21).
In 37 patients with naive PBC, UDCA was oral-
ly administered for 6 months, and changes in the gut 
microbiota were evaluated before and after treat-
ment. The abundances of Haemophilus, Veillonella, 
Streptococcus, and Pseudomonas decreased after 
UDCA treatment, and those of Sutterella, Oscillospi-
ra, and Bacteroides increased after UDCA treatment 
in PBC patients26).
Conclusion
These findings suggest that the gut and oral mi-
crobiota may play different roles in the pathophysiol-
ogy of AIH and PBC. Further studies of the estab-
lishment and modification of the gut and oral 
microbiota structure may contribute to the develop-
ment of a therapeutic strategy for patients with au-
toimmune liver disease.
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